Professor of Medicine
University at Buffalo, SUNY
Buffalo, NY, United States
Sanjay Sethi, MD, is a Professor of Medicine at the University of Buffalo (UB), SUNY, where he is Chief of the Pulmonary/Critical Care/Sleep Medicine Division, Assistant Vice President for Health Sciences, Director of the Clinical Research Office and Deputy Director of the UB Clinical and Translational Science Institute. His main research interests include chronic obstructive pulmonary disease and respiratory infections, specifically focused on exacerbations, new therapeutics and innate lung defense. He has conducted and led bench, translational and clinical research including multiple single and multi-site clinical trials. Dr Sethi has co-authored more than 240 research articles, reviews and book chapters in many peer-reviewed medical journals including New England Journal of Medicine, JAMA, Science Translational Medicine, PNAS and American Journal of Respiratory and Critical Care Medicine, that has been widely cited and has a current Google scholar h-index of 74. His current research funding includes grants from the NIH, DOD, VA and several pharmaceutical companies. He is a member of the editorial board for several publications. He was a member of the lung cellular, molecular, and immunobiology study section of the National Institutes of Health (NIH) and the Pulmonary study section of the VA, and is an ad hoc reviewer for several North American and International research funding agencies.
Dr. Sethi is currently active in several professional organizations including the American Thoracic Society where he has chaired the Clinical Problems program committee and the Clinical Problems Assembly. He has served as a consultant on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for COPD, and was a member of the Department of Veterans Affairs and Department of Defense COPD Guideline Development Committee. Additionally, he is a distinguished speaker presenting papers both nationally and internationally, many with COPD and Respiratory Infections as the primary focus.
Disclosure(s): AstraZenca: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer Ingelheim: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Chiesi Farmaceutici: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Glaxo Smith Kline: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Nuvaira: Advisor/Consultant (Ongoing); PulmonX: Advisor/Consultant (Ongoing)
102 - Chronic Lung Disease: From Biomarkers to New Treatments
Friday, October 13, 2023
8:00 AM – 9:00 AM US ET
1049 - Persistent Airway Infection in COPD
Friday, October 13, 2023
8:30 AM – 9:00 AM US ET